808 lines
212 KiB
Text
808 lines
212 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK574724">
|
|
<meta name="ncbi_domain" content="niceng203er11">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK574724/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence reviews for managing anaemia with IV iron in people with GFR category G5 who are on dialysis - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence reviews for managing anaemia with IV iron in people with GFR category G5 who are on dialysis - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_title" content="Evidence reviews for managing anaemia with IV iron in people with GFR category G5 who are on dialysis">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2021/08">
|
|
<meta name="citation_pmid" content="34672501">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK574724/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence reviews for managing anaemia with IV iron in people with GFR category G5 who are on dialysis">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Date" content="2021/08">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK574724/">
|
|
<meta name="og:title" content="Evidence reviews for managing anaemia with IV iron in people with GFR category G5 who are on dialysis">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK574724/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng203er11-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng203er11/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK574724/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8CF5387D700911000000000091007D.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK574724/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK574724/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK574724/&text=Evidence%20reviews%20for%20managing%20anaemia%20with%20IV%20iron%20in%20people%20with%20GFR%20category%20G5%20who%20are%20on%20dialysis"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK574724/?report=classic">Switch to classic view</a><a href="/books/n/niceng203er11/pdf/">PDF (2.3M)</a><a href="/books/n/niceng203er11/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK574724%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8CF5387D700911000000000091007D.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng203er11-lrg.png" alt="Cover of Evidence reviews for managing anaemia with IV iron in people with GFR category G5 who are on dialysis" /></a></div><div class="bkr_bib"><h1 id="_NBK574724_"><span itemprop="name">Evidence reviews for managing anaemia with IV iron in people with GFR category G5 who are on dialysis</span></h1><div class="subtitle">Chronic kidney disease</div><p><b>Evidence review K</b></p><p><i>NICE Guideline, No. 203</i></p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2021 Aug</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-4233-6</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2021.</div></div><div class="bkr_clear"></div></div><div id="niceng203er11.s1"><h2 id="_niceng203er11_s1_">Managing anaemia with IV iron in people with GFR category G5 who are on dialysis</h2><div id="niceng203er11.s1.1"><h3>1.1. Review question</h3><p>For people with glomerular filtration rate (GFR) category G5 who are on dialysis, what amount of intravenous (IV) iron is most clinically and cost effective in managing anaemia and its associated outcomes?</p><div id="niceng203er11.s1.1.1"><h4>1.1.1. Introduction</h4><p>Many people with chronic kidney disease (CKD) or established renal failure also develop associated anaemia. The prevalence of anaemia associated with CKD increases progressively with GFR category (anaemia of CKD can occur across all stages of CKD, starting from category G2), especially when the patient reaches category G4 or G5. Anaemia of CKD contributes significantly to the burden of CKD. However, it is potentially reversible and manageable with appropriate identification and treatment.</p><p>The NICE guideline on chronic kidney disease: managing anaemia (<a href="https://www.nice.org.uk/guidance/ng8" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE guideline NG8</a>) was reviewed in 2017 as part of NICE’s surveillance programme. As part of the scoping process, NICE identified new areas not included in the surveillance report for which the evidence needed to be reviewed. One of these areas was IV iron for the treatment of anaemia associated with CKD.</p><p>The aim of this review is to determine what amount of IV iron is most clinically and cost effective in managing anaemia and its associated outcomes for people with GFR category G5who are on dialysis. This review identified randomised controlled trials (RCTs) that fulfilled the conditions specified in <a class="figpopup" href="/books/NBK574724/table/niceng203er11.tab1/?report=objectonly" target="object" rid-figpopup="figniceng203er11tab1" rid-ob="figobniceng203er11tab1">Table 1</a>. For full details of the review protocol, see <a href="#niceng203er11.appa">Appendix A</a>.</p></div><div id="niceng203er11.s1.1.2"><h4>1.1.2. Summary of the protocol</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab1"><a href="/books/NBK574724/table/niceng203er11.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab1" rid-ob="figobniceng203er11tab1"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab1/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab1/?report=previmg" alt="Table 1. PICO table for IV iron in people with GFR category G5 who are on dialysis." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab1"><a href="/books/NBK574724/table/niceng203er11.tab1/?report=objectonly" target="object" rid-ob="figobniceng203er11tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO table for IV iron in people with GFR category G5 who are on dialysis. </p></div></div></div><div id="niceng203er11.s1.1.3"><h4>1.1.3. Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>. Methods specific to this review question are described in the review protocol in <a href="#niceng203er11.appa">Appendix A</a> and the methods section in <a href="#niceng203er11.appb">Appendix B</a>.</p><p>Declarations of interest were recorded according to <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s conflicts of interest policy</a>.</p><p>The following methods were specific for this review:
|
|
<ol><li class="half_rhythm"><div>The evidence is reported separately for adults and for children and young people (up to the age of 18 years) and pooled within the same age group.</div></li><li class="half_rhythm"><div>Some of the evidence was divided based on IV iron dose into high and low dose based on the higher and lower doses given in the trials. This included 3 trials for children and young people (<a class="bibr" href="#niceng203er11.s1.1.ref5" rid="niceng203er11.s1.1.ref5">Goldstein 2013</a>, <a class="bibr" href="#niceng203er11.s1.1.ref10" rid="niceng203er11.s1.1.ref10">Ruiz-Jaramillo 2004</a>, and <a class="bibr" href="#niceng203er11.s1.1.ref12" rid="niceng203er11.s1.1.ref12">Warady 2005</a>) and 5 trials for adults (<a class="bibr" href="#niceng203er11.s1.1.ref2" rid="niceng203er11.s1.1.ref2">Besarab 2000</a>, <a class="bibr" href="#niceng203er11.s1.1.ref4" rid="niceng203er11.s1.1.ref4">Charytan 2013</a>, <a class="bibr" href="#niceng203er11.s1.1.ref7" rid="niceng203er11.s1.1.ref7">MacDougall 2019</a>, <a class="bibr" href="#niceng203er11.s1.1.ref8" rid="niceng203er11.s1.1.ref8">Nissenson 1999</a>, and <a class="bibr" href="#niceng203er11.s1.1.ref11" rid="niceng203er11.s1.1.ref11">Wan 2018</a>). The committee agreed that since it was interested in the relative effects, the actual dose and iron preparation were less important. Therefore, this evidence was divided into high and low dose irrespective of the IV iron preparation and based on what the trial reported as high or low.</div></li><li class="half_rhythm"><div>The rest of trials reported different IV iron preparations in each arm with the same dose for all arms (<a class="bibr" href="#niceng203er11.s1.1.ref9" rid="niceng203er11.s1.1.ref9">Roe 1996</a>, <a class="bibr" href="#niceng203er11.s1.1.ref3" rid="niceng203er11.s1.1.ref3">Bhandari 2015</a>, <a class="bibr" href="#niceng203er11.s1.1.ref6" rid="niceng203er11.s1.1.ref6">Hsiao 2016</a>, and <a class="bibr" href="#niceng203er11.s1.1.ref1" rid="niceng203er11.s1.1.ref1">Akcicek 1997</a>). These trials were reported separately.</div></li><li class="half_rhythm"><div><a class="bibr" href="#niceng203er11.s1.1.ref11" rid="niceng203er11.s1.1.ref11">Wan (2018)</a> was a crossover trial but the committee did not consider the washout period to be appropriate for patients receiving Erythropoeitin Stimulating Agents. Therefore, data were only extracted from the first study period.</div></li><li class="half_rhythm"><div>For <a class="bibr" href="#niceng203er11.s1.1.ref1" rid="niceng203er11.s1.1.ref1">Akcicek (1997)</a>, data was taken only from the first study period from this crossover trial because paired t-tests were not reported and there was not enough data from the study to approximate a paired analysis. Therefore, this trial was regarded as a parallel trial rather than as a crossover trial.</div></li></ol></p></div><div id="niceng203er11.s1.1.4"><h4>1.1.4. Effectiveness evidence</h4><div id="niceng203er11.s1.1.4.1"><h5>1.1.4.1. Included studies</h5><p>A systematic search was carried out to identify RCTs and systematic reviews of RCTs, which found 554 references (see <a href="#niceng203er11.appc">Appendix C</a> for the literature search strategy). After screening at title and abstract level, 482 references were excluded. Full texts were ordered to be screened for 72 references. In total, 12 RCTs were included based on their relevance to the review protocol (<a href="#niceng203er11.appa">Appendix A</a>). The clinical evidence study selection is presented as a PRISMA diagram in <a href="#niceng203er11.appd">Appendix D</a>.</p><p>A second set of searches was conducted at the end of the guideline development process for all updated review questions using the original search strategies, to capture papers published whilst the guideline was being developed. This search returned 26 references for this review question, these were screened on title and abstract. Two references were ordered for full text screening. None of these references were included based on their relevance to the review protocol (<a href="#niceng203er11.appa">Appendix A</a>).</p><p>See <a href="#niceng203er11.s1.1.rl.r1">section 1.1.12 References – included studies</a> for a list of references for included studies.</p></div><div id="niceng203er11.s1.1.4.2"><h5>1.1.4.2. Excluded studies</h5><p>See <a href="#niceng203er11.appk">Appendix K</a> for a list of excluded studies with the primary reason for exclusion.</p></div></div><div id="niceng203er11.s1.1.5"><h4>1.1.5. Summary of RCTs included in the effectiveness evidence</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab2"><a href="/books/NBK574724/table/niceng203er11.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab2" rid-ob="figobniceng203er11tab2"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab2/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab2/?report=previmg" alt="Table 2. IV iron high dose vs low dose in children and young people." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab2"><a href="/books/NBK574724/table/niceng203er11.tab2/?report=objectonly" target="object" rid-ob="figobniceng203er11tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">IV iron high dose vs low dose in children and young people. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab3"><a href="/books/NBK574724/table/niceng203er11.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab3" rid-ob="figobniceng203er11tab3"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab3/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab3/?report=previmg" alt="Table 3. IV iron high dose vs low dose in adults." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab3"><a href="/books/NBK574724/table/niceng203er11.tab3/?report=objectonly" target="object" rid-ob="figobniceng203er11tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">IV iron high dose vs low dose in adults. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab4"><a href="/books/NBK574724/table/niceng203er11.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab4" rid-ob="figobniceng203er11tab4"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab4/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab4/?report=previmg" alt="Table 4. IV iron dextran MW 267,000 vs IV iron dextran MW 96,000, adults." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab4"><a href="/books/NBK574724/table/niceng203er11.tab4/?report=objectonly" target="object" rid-ob="figobniceng203er11tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">IV iron dextran MW 267,000 vs IV iron dextran MW 96,000, adults. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab5"><a href="/books/NBK574724/table/niceng203er11.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab5" rid-ob="figobniceng203er11tab5"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab5/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab5/?report=previmg" alt="Table 5. IV iron sucrose (500mg) vs IV iron isomaltoside 1000 (500mg), adults, week 6." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab5"><a href="/books/NBK574724/table/niceng203er11.tab5/?report=objectonly" target="object" rid-ob="figobniceng203er11tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">IV iron sucrose (500mg) vs IV iron isomaltoside 1000 (500mg), adults, week 6. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab6"><a href="/books/NBK574724/table/niceng203er11.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab6" rid-ob="figobniceng203er11tab6"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab6/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab6/?report=previmg" alt="Table 6. IV iron sucrose (1000mg) vs IV ferric chloride hexahydrate (1000mg), adults, week 10." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab6"><a href="/books/NBK574724/table/niceng203er11.tab6/?report=objectonly" target="object" rid-ob="figobniceng203er11tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">IV iron sucrose (1000mg) vs IV ferric chloride hexahydrate (1000mg), adults, week 10. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab7"><a href="/books/NBK574724/table/niceng203er11.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab7" rid-ob="figobniceng203er11tab7"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab7/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab7/?report=previmg" alt="Table 7. IV ferric saccharate (100mg/week) vs IV ferric saccharate (2 × 50mg/week), adults, 2 months." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab7"><a href="/books/NBK574724/table/niceng203er11.tab7/?report=objectonly" target="object" rid-ob="figobniceng203er11tab7">Table 7</a></h4><p class="float-caption no_bottom_margin">IV ferric saccharate (100mg/week) vs IV ferric saccharate (2 × 50mg/week), adults, 2 months. </p></div></div><p>See <a href="#niceng203er11.appe">Appendix E</a> for full evidence tables.</p></div><div id="niceng203er11.s1.1.6"><h4>1.1.6. Summary of the effectiveness evidence</h4><div id="niceng203er11.s1.1.6.1"><h5>Children and young people</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab8"><a href="/books/NBK574724/table/niceng203er11.tab8/?report=objectonly" target="object" title="Table 8" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab8" rid-ob="figobniceng203er11tab8"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab8/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab8/?report=previmg" alt="Table 8. IV iron high dose vs low dose." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab8"><a href="/books/NBK574724/table/niceng203er11.tab8/?report=objectonly" target="object" rid-ob="figobniceng203er11tab8">Table 8</a></h4><p class="float-caption no_bottom_margin">IV iron high dose vs low dose. </p></div></div></div><div id="niceng203er11.s1.1.6.2"><h5>Adults</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab9"><a href="/books/NBK574724/table/niceng203er11.tab9/?report=objectonly" target="object" title="Table 9" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab9" rid-ob="figobniceng203er11tab9"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab9/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab9/?report=previmg" alt="Table 9. IV iron high dose vs low dose." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab9"><a href="/books/NBK574724/table/niceng203er11.tab9/?report=objectonly" target="object" rid-ob="figobniceng203er11tab9">Table 9</a></h4><p class="float-caption no_bottom_margin">IV iron high dose vs low dose. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab10"><a href="/books/NBK574724/table/niceng203er11.tab10/?report=objectonly" target="object" title="Table 10" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab10" rid-ob="figobniceng203er11tab10"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab10/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab10/?report=previmg" alt="Table 10. IV iron dextran MW 267,000 vs IV iron dextran MW 96,000, adults." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab10"><a href="/books/NBK574724/table/niceng203er11.tab10/?report=objectonly" target="object" rid-ob="figobniceng203er11tab10">Table 10</a></h4><p class="float-caption no_bottom_margin">IV iron dextran MW 267,000 vs IV iron dextran MW 96,000, adults. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab11"><a href="/books/NBK574724/table/niceng203er11.tab11/?report=objectonly" target="object" title="Table 11" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab11" rid-ob="figobniceng203er11tab11"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab11/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab11/?report=previmg" alt="Table 11. IV iron sucrose (500mg) vs IV iron isomaltoside 1000 (500mg), adults, week 6." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab11"><a href="/books/NBK574724/table/niceng203er11.tab11/?report=objectonly" target="object" rid-ob="figobniceng203er11tab11">Table 11</a></h4><p class="float-caption no_bottom_margin">IV iron sucrose (500mg) vs IV iron isomaltoside 1000 (500mg), adults, week 6. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab12"><a href="/books/NBK574724/table/niceng203er11.tab12/?report=objectonly" target="object" title="Table 12" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab12" rid-ob="figobniceng203er11tab12"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab12/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab12/?report=previmg" alt="Table 12. IV iron sucrose (1000mg) vs IV ferric chloride hexahydrate (1000mg), adults, week 10." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab12"><a href="/books/NBK574724/table/niceng203er11.tab12/?report=objectonly" target="object" rid-ob="figobniceng203er11tab12">Table 12</a></h4><p class="float-caption no_bottom_margin">IV iron sucrose (1000mg) vs IV ferric chloride hexahydrate (1000mg), adults, week 10. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11tab13"><a href="/books/NBK574724/table/niceng203er11.tab13/?report=objectonly" target="object" title="Table 13" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11tab13" rid-ob="figobniceng203er11tab13"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.tab13/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.tab13/?report=previmg" alt="Table 13. IV ferric saccharate (100mg/week) vs IV ferric saccharate (2 × 50mg/week), adults, 2 months." /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.tab13"><a href="/books/NBK574724/table/niceng203er11.tab13/?report=objectonly" target="object" rid-ob="figobniceng203er11tab13">Table 13</a></h4><p class="float-caption no_bottom_margin">IV ferric saccharate (100mg/week) vs IV ferric saccharate (2 × 50mg/week), adults, 2 months. </p></div></div><p>See <a href="#niceng203er11.appg">Appendix G</a> for full GRADE tables.</p></div></div><div id="niceng203er11.s1.1.7"><h4>1.1.7. Economic evidence</h4><div id="niceng203er11.s1.1.7.1"><h5>1.1.7.1. Included studies</h5><p>A search was conducted to identify economic evaluations relevant to the review question (see <a href="#niceng203er11.appc">Appendix C</a>). The search was not date limited. A total of 530 records were returned, 519 of which were excluded on the basis of title and abstract. The remaining 11 studies were fully inspected, and none were included in the synthesis. No additional studies were identified during inspection of the full publications and reference lists.</p></div><div id="niceng203er11.s1.1.7.2"><h5>1.1.7.2. Excluded studies</h5><p>Details of excluded studies are provided in <a href="#niceng203er11.appk">Appendix K</a>.</p></div></div><div id="niceng203er11.s1.1.8"><h4>1.1.8. Summary of included economic evidence</h4><p>No economic evaluations relevant to the review question were found.</p></div><div id="niceng203er11.s1.1.9"><h4>1.1.9. Economic model</h4><p>No economic modelling was undertaken for this review question.</p></div><div id="niceng203er11.s1.1.10"><h4>1.1.10. The committee’s discussion and interpretation of the evidence</h4><div id="niceng203er11.s1.1.10.1"><h5>1.1.10.1. The outcomes that matter most</h5><p>The committee agreed that even though the majority of the studies included in the review only reported short term follow-ups and improvements in Hb or serum ferritin (most frequently reported outcomes), longer term outcomes were the key outcomes for people (adults, children and young people) with a clinical diagnosis of anaemia and CKD 5 who are on dialysis. This includes long term maintenance of Hb level and serum ferritin level as well as events such as all-cause mortality and CV mortality. The committee also agreed that Hb level, other markers of anaemia, adverse events, incidence of blood transfusions, and quality of life were also important outcomes.</p></div><div id="niceng203er11.s1.1.10.2"><h5>1.1.10.2. The quality of the evidence</h5><p>Overall, the quality of the evidence varied from high to very low (most of the evidence was low and very low), with the main reasons for downgrading being due to imprecision of the evidence on the effect size of the amount of IV iron in managing anaemia and risk of bias of included studies. In most of the pairwise comparisons, imprecision was considered to be serious (95% confidence interval crossing one end of the defined MID interval [0.8, 1.25 for dichotomous outcomes or 0.2 for continuous outcomes]) or very serious (95% confidence interval crossing both ends of the defined MID interval). Risk of bias for some of the included studies was due to lack of detailed report of the randomisation process, lack of report that protocols were pre-registered, or the assignment of interventions was not well described. The committee expressed some concern that the maximum follow-up for Hb measurements was 3 months.</p><p>The committee noted that many of the included studies had a small sample size, short follow-up and reported only biochemical or surrogate outcomes. One study of high quality was large and had long follow-up for most of the outcomes including all-cause mortality and CV mortality (PIVOTAL trial, <a class="bibr" href="#niceng203er11.s1.1.ref7" rid="niceng203er11.s1.1.ref7">MacDougall et al. 2019</a>).</p><p>The committee noted that there was limited evidence for quality of life and that only 2 studies reported data on this outcome, and the data was not reported in an extractable format (raw data was not reported).</p></div><div id="niceng203er11.s1.1.10.3"><h5>1.1.10.3. Benefits and harms</h5><p>For the purposes of the review, the evidence was divided based on the amount of IV iron into ‘high’ and ‘low’ dose (when possible). The committee agreed that since they were interested in relative effects, this was an appropriate thing to do.</p><p>The evidence for adults showed that high-dose intravenous iron was clinically and significantly better than a low-dose regimen at increasing levels of serum ferritin and haemoglobin as well as increasing the percentage of haematocrit in the short to medium term. The committee agreed that the type of iron preparation was not relevant and that there was no reason to recommend a specific preparation. It did however note that not all iron compounds are the same and a bio-equivalent amount of iron would be needed. They also highlighted that there are differences between iron preparations that affect their bioequivalence. Therefore, pharmacist advice is likely to be needed when choosing iron preparations. The committee provided an example regimen for adults using a high dose of iron sucrose. The example regimen was chosen because it was the dose and formulation used in a recent, large high-quality, UK based randomised controlled trial (PIVOTAL trial, <a class="bibr" href="#niceng203er11.s1.1.ref7" rid="niceng203er11.s1.1.ref7">MacDougall et al. 2019</a>). The committee agreed that providing a clear example from the evidence could help guide practice, however they were also very clear that the choice of preparation should be based on local availability and policies and that they did not want to recommend a specific formulation. Therefore, the committee highlighted that iron sucrose was only an example and this was the reason why they suggested to use a bioequivalent dose of iron. The committee further noted that the inclusion criteria for the trial (transferrin saturation <30%, serum ferritin 400 micrograms/litre) differed from the criteria for diagnosing iron deficiency in this NICE guideline (transferrin saturation <20%, serum ferritin <100 micrograms/litre). It agreed that the regimen was still appropriate when using the NICE diagnostic criteria. Ultimately, the choice of preparation should be based on local availability and policies. Therefore, it made a strong recommendation to use high dose iron in people diagnosed with iron deficiency because the trial was a large trial at low risk of bias that improved the certainty of the evidence.</p><p>The evidence for adults also showed that adverse events were not meaningfully different between high-dose and low-dose of intravenous iron. Therefore, it is likely that high-dose intravenous iron does not increase the risk of adverse events compared to low-dose.</p><p>The evidence for children and young people showed that high-dose intravenous iron was clinically and significantly better than a low-dose regimen at increasing levels of serum ferritin in the short to medium term. Based on this limited evidence, the committee agreed that using the highest value of IV iron recommended by the BNF for children was the appropriate amount of iron to give to children and young people, but noted that IV iron use in children is off license either in all children and young people, or in children under 14 (depending on the preparation). The committee also noted that for children and young people it was not uncommon to see a ‘functional iron deficiency’ with normal or high ferritin levels but low Hb and profound anaemia who only respond to very high doses of iron. It agreed that clinicians do not withhold the iv iron where ferritin is high if other, more precise estimates of iron status (e.g. reticulocyte haemoglobin, hypochromic red blood cells) are out of range In these cases clinical judgment would dictate whether or not to give or withhold IV iron. The committee were unsure of the long-term consequences of high ferritin levels in these children and young people and made a research recommendation to address this uncertainty.</p><p>The committee was aware that, in some areas, for people who are on home dialysis, the first dose of IV iron is administered in hospital or in a dialysis centre and the rest of the treatment is given at home or self-administered. The committee discussed the benefits and risks of this, but it was also aware of a MHRA alert on intravenous iron and serious hypersensitivity reactions. The MHRA information on administering intravenous iron states that ‘intravenous iron products should only be administered when staff trained to evaluate and manage anaphylactic or anaphylactoid reactions – as well as resuscitation facilities – are immediately available.’ The committee therefore agreed that intravenous iron should not be administered at home.</p><p>Most of the evidence was from studies including participants who were on haemodialysis and receiving ESA therapy. Therefore, the committee agreed that more research would help to inform future guidance on intravenous iron for people with GFR category G5 who are on peritoneal dialysis or who are on dialysis but not having ESA therapy.</p></div><div id="niceng203er11.s1.1.10.4"><h5>1.1.10.4. Cost effectiveness and resource use</h5><p>The committee was not presented with any formal cost effectiveness evidence. Recommendations are not expected to result in a substantial resource impact, as the committee advised that recommendations are consistent with current practice and IV iron is reasonably inexpensive. Furthermore, in the PIVOTAL trial, people in the high-dose iron group received a lower dose of erythropoiesis-stimulating agent compared with people in the low-dose iron group (<a class="bibr" href="#niceng203er11.s1.1.ref7" rid="niceng203er11.s1.1.ref7">Macdougall et al. 2019</a>). Given the high costs associated with erythropoiesis-stimulating agents, any excess treatment costs, including changing the frequency of treatment, associated with high-dose compared with low-dose iron are likely to be offset by the reduction in erythropoiesis-stimulating agent dose.</p></div><div id="niceng203er11.s1.1.10.5"><h5>1.1.10.5. Other factors the committee took into account</h5><p>The committee agreed that there were no equality issues that could arise from the recommendations they made. They highlighted that there were no physiological differences that could affect the response to treatment with IV iron. The committee agreed to remove a statement from recommendation 1.9.25 which contradicted updated guidance on IV iron in people having in-centre haemodialysis. The 2015 guideline recommended to administered IV iron at a low dose. The updated guideline recommends high-dose IV iron.</p></div></div><div id="niceng203er11.s1.1.11"><h4>1.1.11. Recommendations supported by this evidence review</h4><p>This evidence review supports recommendations 1.9.18 and the research recommendations on IV iron for adults, children and young people with GFR category 5 who are on peritoneal dialysis and on the long-term consequences of high ferritin levels (>800 micrograms/litre) in children and young people with CKD (see <a href="#niceng203er11.appl">Appendix L</a> for further details about the research recommendation).</p></div><div id="niceng203er11.s1.1.rl.r1"><h4>1.1.12. References – included studies</h4><ul class="simple-list"><div id="niceng203er11.s1.1.rl.r1.1"><h5>1.1.12.1. Effectiveness</h5><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref1">Akcicek, F, Ozkahya, M, Cirit, M
|
|
et al. (1997) The efficiency of fractionated parenteral iron treatment in CAPD patients.. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis
|
|
13: 109–12 [<a href="https://pubmed.ncbi.nlm.nih.gov/9360661" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9360661</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref2">Besarab, A, Amin, N, Ahsan, M
|
|
et al. (2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients.. Journal of the American Society of Nephrology : JASN
|
|
11(3): 530–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/10703677" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10703677</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref3">Bhandari, Sunil, Kalra, Philip A, Kothari, Jatin
|
|
et al. (2015) A randomized, open-label trial of iron isomaltoside 1000 (Monofer) compared with iron sucrose (Venofer) as maintenance therapy in haemodialysis patients.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
|
|
30(9): 1577–89 [<a href="/pmc/articles/PMC4550440/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4550440</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25925701" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25925701</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref4">Charytan, Chaim, Bernardo, Marializa V, Koch, Todd A
|
|
et al. (2013) Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
|
|
28(4): 953–64 [<a href="https://pubmed.ncbi.nlm.nih.gov/23222534" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23222534</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref5">Goldstein, Stuart L; Morris, David; Warady, Bradley A (2013) Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.. American journal of kidney diseases : the official journal of the National Kidney Foundation
|
|
61(4): 588–97 [<a href="https://pubmed.ncbi.nlm.nih.gov/23245582" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23245582</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref6">Hsiao
|
|
P.-J., Chan
|
|
J.-S., Wu
|
|
K.-L.
|
|
et al. (2016) Comparison of short-term efficacy of iron sucrose with those of ferric chloride in hemodialysis patients: An open-label study. Journal of Research in Medical Sciences
|
|
21(7): 102 [<a href="/pmc/articles/PMC5244645/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5244645</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28163745" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28163745</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref7">Macdougall, Iain C, White, Claire, Anker, Stefan D
|
|
et al. (2019) Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.. The New England journal of medicine
|
|
380(5): 447–458 [<a href="https://pubmed.ncbi.nlm.nih.gov/30365356" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30365356</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref8">Nissenson, A R, Lindsay, R M, Swan, S
|
|
et al. (1999) Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.. American journal of kidney diseases : the official journal of the National Kidney Foundation
|
|
33(3): 471–82 [<a href="https://pubmed.ncbi.nlm.nih.gov/10070911" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10070911</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref9">Roe, D J, Harford, A M, Zager, P G
|
|
et al. (1996) Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents.. American journal of kidney diseases : the official journal of the National Kidney Foundation
|
|
28(6): 855–60 [<a href="https://pubmed.ncbi.nlm.nih.gov/8957037" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8957037</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref10">Ruiz-Jaramillo, Ma de la Cruz, Guizar-Mendoza, Juan Manuel, Gutierrez-Navarro, Maria de Jesus
|
|
et al. (2004) Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study.. Pediatric nephrology (Berlin, Germany)
|
|
19(1): 77–81 [<a href="https://pubmed.ncbi.nlm.nih.gov/14634860" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14634860</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref11">Wan, Li and Zhang, Dongliang (2018) Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.. International urology and nephrology
|
|
50(8): 1511–1518 [<a href="https://pubmed.ncbi.nlm.nih.gov/29946818" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29946818</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref12">Warady, Bradley A, Zobrist, R Howard, Wu, Jingyang
|
|
et al. (2005) Sodium ferric gluconate complex therapy in anemic children on hemodialysis.. Pediatric nephrology (Berlin, Germany)
|
|
20(9): 1320–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/15971073" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15971073</span></a>]</div></p></li></ul></div><div id="niceng203er11.s1.1.rl.r1.2"><h5>1.1.12.2. Other</h5><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref13">Pergola
|
|
PE, Pecoits-Filho
|
|
R, Winkelmayer
|
|
WC, et al. (2019) Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review. Pharmacoecon Open. 2019
|
|
Apr
|
|
9 [Epub ahead of print] [<a href="/pmc/articles/PMC6861396/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6861396</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30968369" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30968369</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="niceng203er11.s1.1.ref14">Norman
|
|
GR, Sloan
|
|
JA, Wyrwich
|
|
KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003
|
|
May;41(5):582–92. [<a href="https://pubmed.ncbi.nlm.nih.gov/12719681" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12719681</span></a>]</div></p></li></ul></div></ul></div></div></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng203er11.appa"><h3>Appendix A. Review protocols</h3><p id="niceng203er11.appa.et1"><a href="/books/NBK574724/bin/niceng203er11-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Review protocol for managing anaemia with IV iron in people with GFR category G5 who are on dialysis</a><span class="small"> (PDF, 263K)</span></p></div><div id="niceng203er11.appb"><h3>Appendix B. Methods</h3><div id="niceng203er11.appb.s1"><h4>Priority screening</h4><p>The reviews undertaken for this guideline all made use of the priority screening functionality with the EPPI-reviewer systematic reviewing software. This uses a machine learning algorithm (specifically, an SGD classifier) to take information on features (1, 2 and 3 word blocks) in the titles and abstract of papers marked as being ‘includes’ or ‘excludes’ during the title and abstract screening process, and re-orders the remaining records from most likely to least likely to be an include, based on that algorithm. This re-ordering of the remaining records occurs every time 25 additional records have been screened.</p><p>Research is currently ongoing as to what are the appropriate thresholds where reviewing of abstract can be stopped, assuming a defined threshold for the proportion of relevant papers it is acceptable to miss on primary screening. As a conservative approach until that research has been completed, the following rules were adopted during the production of this guideline:
|
|
<ul><li class="half_rhythm"><div>In every review, at least 50% of the identified abstract (or 1,000 records, if that is a greater number) were always screened.</div></li><li class="half_rhythm"><div>After this point, screening was only terminated if a pre-specified threshold was met for a number of abstracts being screened without a single new include being identified. This threshold was set according to the expected proportion of includes in the review (with reviews with a lower proportion of includes needing a higher number of papers without an identified study to justify termination), and was always a minimum of 250.</div></li><li class="half_rhythm"><div>A random 10% sample of the studies remaining in the database when the threshold were additionally screened, to check if a substantial number of relevant studies were not being correctly classified by the algorithm, with the full database being screened if concerns were identified.</div></li></ul></p><p>As an additional check to ensure this approach did not miss relevant studies, the included studies lists of included systematic reviews were searched to identify any papers not identified through the primary search.</p></div><div id="niceng203er11.appb.s2"><h4>Evidence synthesis and meta-analyses</h4><p>Where possible, meta-analyses were conducted to combine the results of quantitative studies for each outcome. For continuous outcomes analysed as mean differences, where change from baseline data were reported in the trials and were accompanied by a measure of spread (for example standard deviation), these were extracted and used in the meta-analysis. Where measures of spread for change from baseline values were not reported, the corresponding values at study end were used and were combined with change from baseline values to produce summary estimates of effect. These studies were assessed to ensure that baseline values were balanced across the treatment groups; if there were significant differences at baseline these studies were not included in any meta-analysis and were reported separately. For continuous outcomes analysed as standardised mean differences, where only baseline and final time point values were available, change from baseline standard deviations were estimated, assuming a correlation coefficient of 0.5.</p></div><div id="niceng203er11.appb.s3"><h4>Evidence of effectiveness of interventions</h4><div id="niceng203er11.appb.s3.1"><h5>Quality assessment</h5><p>Individual RCTs and quasi-randomised controlled trials were quality assessed using the Cochrane Risk of Bias Tool. Other study designs were quality assessed using the ROBINS-I tool. Each individual study was classified into one of the following three groups:
|
|
<ul><li class="half_rhythm"><div>Low risk of bias – The true effect size for the study is likely to be close to the estimated effect size.</div></li><li class="half_rhythm"><div>Moderate risk of bias – There is a possibility the true effect size for the study is substantially different to the estimated effect size.</div></li><li class="half_rhythm"><div>High risk of bias – It is likely the true effect size for the study is substantially different to the estimated effect size.</div></li></ul></p><p>Each individual study was also classified into one of three groups for directness, based on if there were concerns about the population, intervention, comparator and/or outcomes in the study and how directly these variables could address the specified review question. Studies were rated as follows:
|
|
<ul><li class="half_rhythm"><div>Direct – No important deviations from the protocol in population, intervention, comparator and/or outcomes.</div></li><li class="half_rhythm"><div>Partially indirect – Important deviations from the protocol in one of the population, intervention, comparator and/or outcomes.</div></li><li class="half_rhythm"><div>Indirect – Important deviations from the protocol in at least two of the following areas: population, intervention, comparator and/or outcomes.</div></li></ul></p></div></div><div id="niceng203er11.appb.s4"><h4>Methods for combining intervention evidence</h4><p>Meta-analyses of interventional data were conducted with reference to the Cochrane Handbook for Systematic Reviews of Interventions (Higgins et al. 2011).</p><p>A pooled relative risk was calculated for dichotomous outcomes (using the Mantel–Haenszel method) reporting numbers of people having an event, and a pooled incidence rate ratio was calculated for dichotomous outcomes reporting total numbers of events. Both relative and absolute risks were presented, with absolute risks calculated by applying the relative risk to the pooled risk in the comparator arm of the meta-analysis (all pooled trials).</p><p>Fixed- and random-effects models (der Simonian and Laird) were fitted for all syntheses, with the presented analysis dependent on the degree of heterogeneity in the assembled evidence. Fixed-effects models were the preferred choice to report, but in situations where the assumption of a shared mean for fixed-effects model were clearly not met, even after appropriate pre-specified subgroup analyses were conducted, random-effects results are presented. Fixed-effects models were deemed to be inappropriate if one or both of the following conditions was met:
|
|
<ul><li class="half_rhythm"><div>Significant between study heterogeneity in methodology, population, intervention or comparator was identified by the reviewer in advance of data analysis. This decision was made and recorded before any data analysis was undertaken.</div></li><li class="half_rhythm"><div>The presence of significant statistical heterogeneity in the fixed-effect meta-analysis, defined as I<sup>2</sup>≥50%.</div></li></ul></p><p>In any meta-analyses where some (but not all) of the data came from studies at high risk of bias, a sensitivity analysis was conducted, excluding those studies from the analysis. Results from both the full and restricted meta-analyses are reported. Similarly, in any meta-analyses where some (but not all) of the data came from indirect studies, a sensitivity analysis was conducted, excluding those studies from the analysis.</p><p>Meta-analyses were performed in Cochrane Review Manager V5.3, with the exception of incidence rate ratio analyses which were carried out in R version 3.3.4.</p></div><div id="niceng203er11.appb.s5"><h4>Minimal clinically important differences (MIDs)</h4><p id="niceng203er11.appb.et1"><a href="/books/NBK574724/bin/niceng203er11-appb-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (138K)</span></p></div><div id="niceng203er11.appb.s6"><h4>GRADE for pairwise meta-analyses of interventional evidence</h4><p id="niceng203er11.appb.et2"><a href="/books/NBK574724/bin/niceng203er11-appb-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (152K)</span></p></div><div id="niceng203er11.appb.s7"><h4>Health economics</h4><p id="niceng203er11.appb.et3"><a href="/books/NBK574724/bin/niceng203er11-appb-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (139K)</span></p></div></div><div id="niceng203er11.appc"><h3>Appendix C. Literature search strategies</h3><p>
|
|
<b>RQ: For people with GFR category G5 who are on dialysis, what amount of intravenous (IV) iron is most clinically and cost effective in managing anaemia and its associated outcomes?</b>
|
|
</p><div id="niceng203er11.appc.s1"><h4>Background to the search</h4><p>A NICE information specialist conducted the literature searches for the evidence review. The searches were originally run between the 17<sup>th</sup> and 20<sup>th</sup> of June 2019 and updated between the 15<sup>th</sup> and 16<sup>th</sup> of September 2020. This search report is compliant with the requirements of <a href="https://osf.io/2rgfa/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PRISMA-S</a>.</p><p>The principal search strategy was developed in MEDLINE (Ovid interface) and adapted, as appropriate, for use in the other sources listed in the protocol, taking into account their size, search functionality and subject coverage.</p><p>The MEDLINE strategy below was quality assured (QA) by trained NICE information specialist. All translated search strategies were peer reviewed to ensure their accuracy. Both procedures were adapted from the <a href="https://www.cadth.ca/resources/finding-evidence/press" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">2016 PRESS Checklist</a>.</p><p>The search results were managed in EPPI-Reviewer v5. Duplicates were removed in EPPI-R5 using a two-step process. First, automated deduplication is performed using a high-value algorithm. Second, manual deduplication is used to assess ‘low-probability’ matches. All decisions made for the review can be accessed via the deduplication history.</p><p>English language limits were applied in adherence to standard NICE practice and the review protocol.</p><p>Limits to exclude conferences in Embase were applied in adherence to standard NICE practice and the review protocol.</p><p>The limit to remove animal studies in the searches was the standard NICE practice, which has been adapted from: Dickersin, K., Scherer, R., & Lefebvre, C. (1994). <a href="https://doi.org/10.1136/bmj.309.6964.1286" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Systematic Reviews: Identifying relevant studies for systematic reviews</a>. <em>BMJ</em>, 309(6964), 1286. [<a href="/pmc/articles/PMC2541778/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2541778</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7718048" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7718048</span></a>]</p></div><div id="niceng203er11.appc.s2"><h4>Clinical searches</h4><p id="niceng203er11.appc.et1"><a href="/books/NBK574724/bin/niceng203er11-appc-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (374K)</span></p></div><div id="niceng203er11.appc.s3"><h4>Cost-effectiveness searches</h4><p id="niceng203er11.appc.et2"><a href="/books/NBK574724/bin/niceng203er11-appc-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (340K)</span></p></div></div><div id="niceng203er11.appd"><h3>Appendix D. Effectiveness evidence study selection</h3><p id="niceng203er11.appd.et1"><a href="/books/NBK574724/bin/niceng203er11-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (146K)</span></p></div><div id="niceng203er11.appe"><h3>Appendix E. Effectiveness evidence tables</h3><p id="niceng203er11.appe.et1"><a href="/books/NBK574724/bin/niceng203er11-appe-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (707K)</span></p></div><div id="niceng203er11.appf"><h3>Appendix F. Forest plots</h3><p id="niceng203er11.appf.et1"><a href="/books/NBK574724/bin/niceng203er11-appf-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Children and young people</a><span class="small"> (PDF, 192K)</span></p><p id="niceng203er11.appf.et2"><a href="/books/NBK574724/bin/niceng203er11-appf-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Adults</a><span class="small"> (PDF, 282K)</span></p></div><div id="niceng203er11.appg"><h3>Appendix G. GRADE tables</h3><p id="niceng203er11.appg.et1"><a href="/books/NBK574724/bin/niceng203er11-appg-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (416K)</span></p></div><div id="niceng203er11.apph"><h3>Appendix H. Economic evidence study selection</h3><p id="niceng203er11.apph.et1"><a href="/books/NBK574724/bin/niceng203er11-apph-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (134K)</span></p></div><div id="niceng203er11.appi"><h3>Appendix I. Economic evidence tables</h3><p>None – no economic evaluations relevant to the review question were found.</p></div><div id="niceng203er11.appj"><h3>Appendix J. Health economic model</h3><p>None – no economic evaluations relevant to the review question were found.</p></div><div id="niceng203er11.appk"><h3>Appendix K. Excluded studies</h3><div id="niceng203er11.appk.s1"><h4>Clinical studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11appktab1"><a href="/books/NBK574724/table/niceng203er11.appk.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11appktab1" rid-ob="figobniceng203er11appktab1"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.appk.tab1/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.appk.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.appk.tab1"><a href="/books/NBK574724/table/niceng203er11.appk.tab1/?report=objectonly" target="object" rid-ob="figobniceng203er11appktab1">Table</a></h4><p class="float-caption no_bottom_margin">- Does not contain a population of people on dialysis Mixed conservative management and RRT</p></div></div></div><div id="niceng203er11.appk.s2"><h4>Economic studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng203er11appktab2"><a href="/books/NBK574724/table/niceng203er11.appk.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng203er11appktab2" rid-ob="figobniceng203er11appktab2"><img class="small-thumb" src="/books/NBK574724/table/niceng203er11.appk.tab2/?report=thumb" src-large="/books/NBK574724/table/niceng203er11.appk.tab2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng203er11.appk.tab2"><a href="/books/NBK574724/table/niceng203er11.appk.tab2/?report=objectonly" target="object" rid-ob="figobniceng203er11appktab2">Table</a></h4></div></div></div></div><div id="niceng203er11.appl"><h3>Appendix L. Research recommendations – full details</h3><div id="niceng203er11.appl.s1"><h4>L.1.1. Research recommendation</h4><p>For adults, children and young people with GFR category G5 who are undergoing peritoneal dialysis, what amount of intravenous (IV) iron is most clinically and cost effective in managing anaemia and its associated outcomes (including quality of life)?</p></div><div id="niceng203er11.appl.s2"><h4>L.1.2. Why this is important</h4><p>Most of the evidence for intravenous iron in managing anaemia was derived from RCTs that recruited people with GFR category G5 who were on haemodialysis. There were only 2 trials recruiting participants on peritoneal dialysis with small sample sizes (<a class="bibr" href="#niceng203er11.s1.1.ref1" rid="niceng203er11.s1.1.ref1">Akcicek 1997</a> [n=17]; <a class="bibr" href="#niceng203er11.s1.1.ref5" rid="niceng203er11.s1.1.ref5">Goldstein 2013</a> [n=36]). As a result, the new recommendation was based on the evidence for haemodialysis.</p><p>Further research needs to explore the clinical and cost-effectiveness of intravenous iron in managing anaemia in a larger group of people with GFR category G5 who are on peritoneal dialysis.</p></div><div id="niceng203er11.appl.s3"><h4>L.1.3. Rationale for research recommendation</h4><p id="niceng203er11.appl.et1"><a href="/books/NBK574724/bin/niceng203er11-appl-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (168K)</span></p></div><div id="niceng203er11.appl.s4"><h4>L.1.4. Modified PICO table</h4><p id="niceng203er11.appl.et2"><a href="/books/NBK574724/bin/niceng203er11-appl-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (150K)</span></p></div><div id="niceng203er11.appl.s5"><h4>L.1.5. Research recommendation</h4><p>What are the long-term consequences of high ferritin levels (>800 micrograms/litre) in children and young people with CKD?</p></div><div id="niceng203er11.appl.s6"><h4>L.1.6. Why this is important</h4><p>The committee agreed that for some children and young people where estimates of iron status (e.g. reticulocyte haemoglobin, hypochromic red blood cells) are out of range, iron would be given clinically even if serum ferritin levels were high. It therefore agreed that it was important to understand the long-term consequences of high serum ferritin.</p></div><div id="niceng203er11.appl.s7"><h4>L.1.7. Rationale for research recommendation</h4><p id="niceng203er11.appl.et3"><a href="/books/NBK574724/bin/niceng203er11-appl-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (182K)</span></p></div><div id="niceng203er11.appl.s8"><h4>L.1.8. Modified PICO table</h4><p id="niceng203er11.appl.et4"><a href="/books/NBK574724/bin/niceng203er11-appl-et4.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (145K)</span></p></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Evidence reviews underpinning recommendation 1.9.18 and research recommendations in the NICE guideline</p><p>This evidence reviews were developed by the Guideline Updates Team</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2021.</div><div class="small"><span class="label">Bookshelf ID: NBK574724</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34672501" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">34672501</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng203er11tab1"><div id="niceng203er11.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO table for IV iron in people with GFR category G5 who are on dialysis</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng203er11.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng203er11.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>Inclusion:</b>
|
|
</p>
|
|
<p>Adults, children and young people with a clinical diagnosis of anaemia and GFR category G5 and who are on dialysis.</p>
|
|
<p>
|
|
<b>Exclusion:</b>
|
|
</p>
|
|
<p>Management of anaemia in people whose anaemia is not principally caused by CKD.</p>
|
|
<p>Ferumoxytol (withdrawn due to safety concerns)</p>
|
|
</td></tr><tr><th id="hd_b_niceng203er11.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><td headers="hd_b_niceng203er11.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>IV iron</b>
|
|
<ul><li class="half_rhythm"><div>Ferric carboxymaltose</div></li><li class="half_rhythm"><div>Iron dextran</div></li><li class="half_rhythm"><div>Iron isomaltoside 1000</div></li><li class="half_rhythm"><div>Iron polymaltose</div></li><li class="half_rhythm"><div>Iron sucrose</div></li><li class="half_rhythm"><div>Sodium ferric gluconate complex (SFGC)</div></li></ul></td></tr><tr><th id="hd_b_niceng203er11.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><td headers="hd_b_niceng203er11.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Other doses/schedules/formulations of IV iron</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng203er11.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome</th><td headers="hd_b_niceng203er11.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All measured over the follow up time of the studies:</p>
|
|
<p><b>Primary outcomes:</b>
|
|
<ul><li class="half_rhythm"><div>Haemoglobin (Hb) level</div></li><li class="half_rhythm"><div>Other markers of anaemia (for example serum ferritin)</div></li><li class="half_rhythm"><div>All-cause mortality</div></li><li class="half_rhythm"><div>CV specific mortality</div></li><li class="half_rhythm"><div>Adverse events (infection, vascular access thrombosis, hypertension, hospitalization, anaphylaxis)</div></li></ul>
|
|
<b>Secondary outcomes:</b>
|
|
<ul><li class="half_rhythm"><div>Incidence of blood transfusions</div></li><li class="half_rhythm"><div>QoL</div></li></ul></p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab2"><div id="niceng203er11.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">IV iron high dose vs low dose in children and young people</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng203er11.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng203er11.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng203er11.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><th id="hd_h_niceng203er11.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><th id="hd_h_niceng203er11.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome measure(s)</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref5" rid="niceng203er11.s1.1.ref5">Goldstein (2013)</a>
|
|
</p>
|
|
<p>N=145</p>
|
|
<p>Follow-up:</p>
|
|
<p>12 weeks</p>
|
|
</td><td headers="hd_h_niceng203er11.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: 2 to 21 years</div></li><li class="half_rhythm"><div>Haemoglobin ≥11.0 to ≤13.5 g/dL</div></li><li class="half_rhythm"><div>Ferritin 800 ng/mL≤</div></li><li class="half_rhythm"><div>Transferrin saturation ≥20% to ≤50%</div></li><li class="half_rhythm"><div>Erythropoietic stimulating agent: stable therapy (±25% of current dose) for 8 weeks or longer prior to the qualifying screening visit</div></li><li class="half_rhythm"><div>Other parameters: dialysis stable regimen for at least 3 months</div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron sucrose (high dose = 2.0 mg/kg)</td><td headers="hd_h_niceng203er11.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>IV iron sucrose (very low dose = 0.5 mg/kg)</p>
|
|
<p>IV iron sucrose (low dose = 1.0 mg/kg)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Hb level</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref10" rid="niceng203er11.s1.1.ref10">Ruiz-Jaramillo (2004)</a>
|
|
</p>
|
|
<p>N=40</p>
|
|
<p>Follow-up:</p>
|
|
<p>6 months</p>
|
|
</td><td headers="hd_h_niceng203er11.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: <16 years</div></li><li class="half_rhythm"><div>Other parameters
|
|
<ul class="circle"><li class="half_rhythm"><div>Anaemia and absolute iron deficiency (ferritin <100 µg/l and transferrin saturation <20%) or functional iron deficiency (ferritin >100 µg/l and transferrin saturation <20% or haematocrit <33%)</div></li></ul></div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV Iron dextran (dose depended on ferritin levels = low dose [6 mg/kg per month])</td><td headers="hd_h_niceng203er11.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV Iron dextran (10-dose courses on body weight = high dose [14.4 mg/g per month])</td><td headers="hd_h_niceng203er11.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Hb level</div></li><li class="half_rhythm"><div>Other markers of anaemia
|
|
<ul class="circle"><li class="half_rhythm"><div>Ferritin</div></li></ul></div></li><li class="half_rhythm"><div>Blood transfusion</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref12" rid="niceng203er11.s1.1.ref12">Warady (2005)</a>
|
|
</p>
|
|
<p>N=66</p>
|
|
<p>Follow-up:</p>
|
|
<p>4 weeks</p>
|
|
</td><td headers="hd_h_niceng203er11.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: 2 to 15 years</div></li><li class="half_rhythm"><div>Erythropoietic stimulating agent: receiving concomitant recombinant human erythropoietin therapy with stable dosing regimen (defined as ≤25% change in the dose during the 4 weeks before treatment assignment)</div></li><li class="half_rhythm"><div>Other parameters
|
|
<ul class="circle"><li class="half_rhythm"><div>need for iron-repletion therapy as reflected by a transferrin saturation of <20% and/or a serum ferritin of <100 ng mL-1</div></li></ul></div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV sodium ferric gluconate complex (low dose = 1.5 mg kg-1)</td><td headers="hd_h_niceng203er11.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV sodium ferric gluconate complex (high dose = 3.0 mg kg-1)</td><td headers="hd_h_niceng203er11.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Hb level</div></li><li class="half_rhythm"><div>Other markers of anaemia
|
|
<ul class="circle"><li class="half_rhythm"><div>Serum ferritin</div></li></ul></div></li><li class="half_rhythm"><div>Adverse events</div></li></ul>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab3"><div id="niceng203er11.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">IV iron high dose vs low dose in adults</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_niceng203er11.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng203er11.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng203er11.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><th id="hd_h_niceng203er11.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><th id="hd_h_niceng203er11.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome measure(s)</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref2" rid="niceng203er11.s1.1.ref2">Besarab (2000)</a>
|
|
</p>
|
|
<p>N=47</p>
|
|
<p>Follow-up:</p>
|
|
<p>6 weeks</p>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: >18 years</div></li><li class="half_rhythm"><div>Haemoglobin ≥9.5 g/dl</div></li><li class="half_rhythm"><div>Ferritin between 150 and 600 ng/ml</div></li><li class="half_rhythm"><div>Transferrin saturation between 19 and 30%</div></li><li class="half_rhythm"><div>Erythropoietic stimulating agent: stable dose for anaemia management over the previous 3 mo (±25%)</div></li><li class="half_rhythm"><div>Medications: no prior adverse reactions to parenteral iron</div></li><li class="half_rhythm"><div>Other parameters: mean cell volume of >80 fl</div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron dextran (low dose = TSAT 20 to 30%)</td><td headers="hd_h_niceng203er11.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron dextran (high dose = TSAT 30 to 50%)</td><td headers="hd_h_niceng203er11.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Hb level</div></li><li class="half_rhythm"><div>Other markers of anaemia
|
|
<ul class="circle"><li class="half_rhythm"><div>Ferritin</div></li></ul></div></li><li class="half_rhythm"><div>All-cause mortality</div></li><li class="half_rhythm"><div>CV specific mortality</div></li><li class="half_rhythm"><div>Adverse events</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref4" rid="niceng203er11.s1.1.ref4">Charytan (2013)</a>
|
|
</p>
|
|
<p>N=97</p>
|
|
<p>Follow-up:</p>
|
|
<p>30 days</p>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: 18–85 years of age if they had at least a 6- month history of dialysis CKD</div></li><li class="half_rhythm"><div>Haemoglobin ≤12.5 g/dL</div></li><li class="half_rhythm"><div>Ferritin ≤500 ng/mL</div></li><li class="half_rhythm"><div>Transferrin saturation ≤30%</div></li><li class="half_rhythm"><div>Other parameters: eligible if they did not anticipate needing repletion therapy (>200 mg of IV iron) during the 30-day study period.</div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV ferric carboxymaltose (low dose = mean dose 200 mg)</td><td headers="hd_h_niceng203er11.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard medical care (high dose = mean dose 561 mg)</td><td headers="hd_h_niceng203er11.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Hb level</div></li><li class="half_rhythm"><div>Other markers of anaemia
|
|
<ul class="circle"><li class="half_rhythm"><div>Ferritin</div></li></ul></div></li><li class="half_rhythm"><div>CV specific mortality</div></li><li class="half_rhythm"><div>Adverse events</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref7" rid="niceng203er11.s1.1.ref7">MacDougall (2019)</a>
|
|
</p>
|
|
<p>N=2141</p>
|
|
<p>Follow-up:</p>
|
|
<p>Median 2.1 years</p>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: >18 years</div></li><li class="half_rhythm"><div>Ferritin <400 μg/L</div></li><li class="half_rhythm"><div>Transferrin saturation <30%</div></li><li class="half_rhythm"><div>Erythropoietic stimulating agent: on ESA therapy</div></li><li class="half_rhythm"><div>Other parameters: Patients established on a chronic haemodialysis program for end-stage renal failure; Clinically stable per the judgment of the investigator; 0–12 months since commencing haemodialysis; Patients who have switched to haemodialysis from peritoneal dialysis or have received previous haemodialysis or renal transplants are eligible to enter the study.</div></li><li class="half_rhythm"><div>Consent: Written informed consent</div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron sucrose (high dose-proactive = 400 mg monthly)</td><td headers="hd_h_niceng203er11.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron sucrose (low dose-reactive = 0 to 400 mg monthly)</td><td headers="hd_h_niceng203er11.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>All-cause mortality</div></li><li class="half_rhythm"><div>CV specific mortality</div></li><li class="half_rhythm"><div>Adverse events</div></li><li class="half_rhythm"><div>Blood transfusion</div></li><li class="half_rhythm"><div>Subgroup analysis</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref8" rid="niceng203er11.s1.1.ref8">Nissenson (1999)</a>
|
|
</p>
|
|
<p>N=88</p>
|
|
<p>Follow-up:</p>
|
|
<p>30 days</p>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: Adults</div></li><li class="half_rhythm"><div>Haemoglobin <10 g/dL</div></li><li class="half_rhythm"><div>Haematocrit ≤32%</div></li><li class="half_rhythm"><div>Ferritin <100 ng/m</div></li><li class="half_rhythm"><div>Transferrin saturation <18%</div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV sodium ferric gluconate complex in sucrose (high dose = 1000mg)</td><td headers="hd_h_niceng203er11.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV sodium ferric gluconate complex in sucrose (low dose = 500mg)</td><td headers="hd_h_niceng203er11.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Hb level</div></li><li class="half_rhythm"><div>Other markers of anaemia
|
|
<ul class="circle"><li class="half_rhythm"><div>Serum ferritin; haematocrit</div></li></ul></div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref11" rid="niceng203er11.s1.1.ref11">Wan (2018)</a>
|
|
</p>
|
|
<p>N=47</p>
|
|
<p>Follow-up:</p>
|
|
<p>3 months</p>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: Adults</div></li><li class="half_rhythm"><div>Haemoglobin maintained at 100–130 (g/l)</div></li><li class="half_rhythm"><div>Ferritin 100–500 (ng/ml)</div></li><li class="half_rhythm"><div>Erythropoietic stimulating agent: treated with recombinant human erythropoietin</div></li><li class="half_rhythm"><div>Other parameters
|
|
<ul class="circle"><li class="half_rhythm"><div>Regular haemodialysis patients (4 h per session and three times a week) with duration of stable haemodialysis more than 6 months; intact parathyroid hormone < 800 (pg/ml); Kt/V of each haemodialysis session >1.2 during the screening period</div></li></ul></div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron sucrose (continuous administration = high dose [1000 mg reached at 1 month])</td><td headers="hd_h_niceng203er11.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron sucrose (intermittent administration = low dose [1000 mg reached at 3 months])</td><td headers="hd_h_niceng203er11.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Hb level</div></li><li class="half_rhythm"><div>Other markers of anaemia
|
|
<ul class="circle"><li class="half_rhythm"><div>Serum ferritin reported as median (25th, 75th range); haematocrit</div></li></ul></div></li></ul>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab4"><div id="niceng203er11.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">IV iron dextran MW 267,000 vs IV iron dextran MW 96,000, adults</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab4_lrgtbl__"><table><thead><tr><th id="hd_h_niceng203er11.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng203er11.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng203er11.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><th id="hd_h_niceng203er11.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><th id="hd_h_niceng203er11.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome measure(s)</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref9" rid="niceng203er11.s1.1.ref9">Roe (1996)</a>
|
|
</p>
|
|
<p>N=20</p>
|
|
<p>Follow-up:</p>
|
|
<p>30 days</p>
|
|
</td><td headers="hd_h_niceng203er11.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Ag: 18 years or older</div></li><li class="half_rhythm"><div>Ferritin <100 µg/L</div></li><li class="half_rhythm"><div>Transferrin saturation <20%</div></li><li class="half_rhythm"><div>Other parameters
|
|
<ul class="circle"><li class="half_rhythm"><div>life expectancy greater than 60 days, were receiving erythropoietin therapy for dialysis associated anaemia (haemoglobin 9 to 12 g/dL)</div></li></ul></div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron dextran MW 267,000 (500 mg)</td><td headers="hd_h_niceng203er11.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron dextran MW 96,000 (500 mg)</td><td headers="hd_h_niceng203er11.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Hb level</div></li><li class="half_rhythm"><div>Other markers of anaemia
|
|
<ul class="circle"><li class="half_rhythm"><div>Serum ferritin</div></li></ul></div></li></ul>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab5"><div id="niceng203er11.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">IV iron sucrose (500mg) vs IV iron isomaltoside 1000 (500mg), adults, week 6</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab5_lrgtbl__"><table><thead><tr><th id="hd_h_niceng203er11.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng203er11.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng203er11.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><th id="hd_h_niceng203er11.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><th id="hd_h_niceng203er11.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome measure(s)</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref3" rid="niceng203er11.s1.1.ref3">Bhandari (2015)</a>
|
|
</p>
|
|
<p>Follow-up:</p>
|
|
<p>6 weeks</p>
|
|
</td><td headers="hd_h_niceng203er11.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: ≥18 years of age with a diagnosis of CKD and on haemodialysis therapy for at least 90 days</div></li><li class="half_rhythm"><div>Haemoglobin between 9.5 and 12.5 g/dL</div></li><li class="half_rhythm"><div>Ferritin <800 ng/mL</div></li><li class="half_rhythm"><div>Transferrin saturation <35%</div></li><li class="half_rhythm"><div>Erythropoietic stimulating agent:</div></li><li class="half_rhythm"><div>dose stable for the previous 4 weeks prior to screening</div></li><li class="half_rhythm"><div>Medications: No IV iron or an average of no >100 mg/week for the previous 4 weeks</div></li><li class="half_rhythm"><div>Other parameters: Life expectancy beyond 12 months</div></li><li class="half_rhythm"><div>Consent: Willing to provide written informed consent</div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron isomaltoside 1000 (500mg)</td><td headers="hd_h_niceng203er11.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron sucrose (500mg)</td><td headers="hd_h_niceng203er11.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Hb level</div></li><li class="half_rhythm"><div>All-cause mortality</div></li><li class="half_rhythm"><div>Adverse events</div></li></ul>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab6"><div id="niceng203er11.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">IV iron sucrose (1000mg) vs IV ferric chloride hexahydrate (1000mg), adults, week 10</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab6_lrgtbl__"><table><thead><tr><th id="hd_h_niceng203er11.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng203er11.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng203er11.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><th id="hd_h_niceng203er11.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><th id="hd_h_niceng203er11.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome measure(s)</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref6" rid="niceng203er11.s1.1.ref6">Hsiao (2016)</a>
|
|
</p>
|
|
<p>N=56</p>
|
|
<p>Follow-up:</p>
|
|
<p>10 weeks</p>
|
|
</td><td headers="hd_h_niceng203er11.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: ≥18 years</div></li><li class="half_rhythm"><div>Haematocrit between 22% and 32%</div></li><li class="half_rhythm"><div>Ferritin <200 μg/L</div></li><li class="half_rhythm"><div>Transferrin saturation <40%</div></li><li class="half_rhythm"><div>Other parameters: regular haemodialysis for at least 3 months; normal serum Vitamin B12 and folic acid concentrations; no blood transfusion in the last 3 months</div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV iron sucrose (1000mg)</td><td headers="hd_h_niceng203er11.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV ferric chloride hexahydrate (1000mg)</td><td headers="hd_h_niceng203er11.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Other markers of anaemia
|
|
<ul class="circle"><li class="half_rhythm"><div>Serum ferritin</div></li><li class="half_rhythm"><div>Haematocrit</div></li></ul></div></li></ul>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab7"><div id="niceng203er11.tab7" class="table"><h3><span class="label">Table 7</span><span class="title">IV ferric saccharate (100mg/week) vs IV ferric saccharate (2 × 50mg/week), adults, 2 months</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab7_lrgtbl__"><table><thead><tr><th id="hd_h_niceng203er11.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng203er11.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_niceng203er11.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><th id="hd_h_niceng203er11.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><th id="hd_h_niceng203er11.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome measure(s)</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#niceng203er11.s1.1.ref1" rid="niceng203er11.s1.1.ref1">Akcicek (1997)</a>
|
|
</p>
|
|
<p>N=17</p>
|
|
<p>Follow-up:</p>
|
|
<p>6 weeks</p>
|
|
</td><td headers="hd_h_niceng203er11.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Age: Adults</div></li><li class="half_rhythm"><div>Haemoglobin <10 g/dL</div></li><li class="half_rhythm"><div>Haematocrit equivalent levels to haemoglobin levels</div></li><li class="half_rhythm"><div>Erythropoietic stimulating agent: average dose 80 ±28 U/kg/week</div></li></ul>
|
|
</td><td headers="hd_h_niceng203er11.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV ferric saccharate (100mg/week)</td><td headers="hd_h_niceng203er11.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV ferric saccharate (2 × 50mg/week)</td><td headers="hd_h_niceng203er11.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Other markers of anaemia
|
|
<ul class="circle"><li class="half_rhythm"><div>Ferritin</div></li><li class="half_rhythm"><div>Haematocrit</div></li></ul></div></li></ul>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab8"><div id="niceng203er11.tab8" class="table"><h3><span class="label">Table 8</span><span class="title">IV iron high dose vs low dose</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcome</th><th id="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - Week 2</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.00</p>
|
|
<p>(−0.64, 0.64)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>a</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - Week 4</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.10</p>
|
|
<p>(−0.78, 0.98)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb 10.5-14.0 g/dL – Week 12</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.76</p>
|
|
<p>(0.42, 1.34)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>c</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb 10.5-14.0 g/dL – Week 12</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.71</p>
|
|
<p>(0.40, 1.25)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>c</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb 10.5-14.0 g/dL – Week 12</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.94</p>
|
|
<p>(0.60, 1.47)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>c</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serum ferritin µg/L or ng mL - Week 2</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 117.20</p>
|
|
<p>(5.37, 229.03)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. Clinically significant effect higher than the MID (113.7)</td></tr><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serum ferritin µg/L or ng mL - Week 4</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 65.30</p>
|
|
<p>(−62.19, 192.79)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serum ferritin µg/L or ng mL – 4 months</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 268.00</p>
|
|
<p>(51.81, 484.19)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. Clinically significant effect higher than the MID (143.15)</td></tr><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blood transfusions, 6 months</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 7.00</p>
|
|
<p>(0.38, 127.32)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>c</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events, week 4</td><td headers="hd_h_niceng203er11.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66</td><td headers="hd_h_niceng203er11.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.94</p>
|
|
<p>(0.06, 14.42)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>c</sup></td><td headers="hd_h_niceng203er11.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng203er11.tab8_1"><p class="no_margin">Serious risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng203er11.tab8_2"><p class="no_margin">Serious risk of bias; serious imprecision</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng203er11.tab8_3"><p class="no_margin">Serious risk of bias; very serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab9"><div id="niceng203er11.tab9" class="table"><h3><span class="label">Table 9</span><span class="title">IV iron high dose vs low dose</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcome</th><th id="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb level ≤12.5 g/dL - Day 30</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.15</p>
|
|
<p>(0.67, 1.97)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - Day 2</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.70</p>
|
|
<p>(0.14, 1.26)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. Clinically significant effect higher than the MID (0.50)</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - Day 14</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.80</p>
|
|
<p>(0.21, 1.39)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. Clinically significant effect higher than the MID (0.50)</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - Day 30</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">175</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.43</p>
|
|
<p>(−0.14, 1.00)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>c</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - Month 3</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.38</p>
|
|
<p>(−0.41, 1.17)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ferritin ng/mL - Day 2</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 190.00</p>
|
|
<p>(32.89, 347.11)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. Clinically significant effect higher than the MID (90.40)</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ferritin ng/mL - Day 14</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 67.00</p>
|
|
<p>(−54.82, 188.82)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ferritin ng/mL - Day 30</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">173</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 59.03</p>
|
|
<p>(21.41, 96.65)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>d</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. There is an effect, but it is less than the defined MID (125.99)</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Haematocrit % - Day 2</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 2.00</p>
|
|
<p>(0.20, 3.80)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. Clinically significant effect higher than the MID (1.77)</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Haematocrit % - Day 14</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 2.20</p>
|
|
<p>(0.22, 4.18)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. Clinically significant effect higher than the MID (1.76)</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Haematocrit % - Day 30</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 2.10</p>
|
|
<p>(0.12, 4.08)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. Clinically significant effect higher than the MID (1.85)</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Haematocrit % - Month 3</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 1.35</p>
|
|
<p>(−0.89, 3.59)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality - 6 months</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 2.50</p>
|
|
<p>(0.11, 58.06)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality - time-to-first event (median follow-up 2.1 years)</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2,141</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.88</p>
|
|
<p>(0.75, 1.02)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>e</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality: subgroups - Catheter access</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">884</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.77</p>
|
|
<p>(0.61, 0.96)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours high dose. Clinically significant effect exceeding the line of no effect</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality: subgroups - Fistula access</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1,257</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.97</p>
|
|
<p>(0.79, 1.19)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>e</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality: subgroups - Diabetes</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">944</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.86</p>
|
|
<p>(0.71, 1.04)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>e</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality: subgroups - Non-diabetes</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1,198</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.89</p>
|
|
<p>(0.70, 1.12)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>e</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality: subgroups - Duration of dialysis <5 months</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">986</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.87</p>
|
|
<p>(0.69, 1.10)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>e</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality: subgroups - Duration of dialysis ≥5 months</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1,155</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.88</p>
|
|
<p>(0.73, 1.07)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>e</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CV mortality - Day 30</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">97</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 5.31</p>
|
|
<p>(0.26, 107.85)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CV mortality - 6 months</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.17</p>
|
|
<p>(0.01, 3.27)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CV mortality - time-to-first event (median follow-up 2.1 years)</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2,141</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.91</p>
|
|
<p>(0.69, 1.20)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>e</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events - ≥1 event, day 30</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">97</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.96</p>
|
|
<p>(0.60, 1.55)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events - time-to-first event (median follow-up 2.1 years)</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2,141</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.01</p>
|
|
<p>(0.95, 1.08)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events: infection - 6 months</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.77</p>
|
|
<p>(0.32, 1.83)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events: infection - time-to-first event (median follow-up 2.1 years)</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2,141</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.00</p>
|
|
<p>(0.88, 1.13)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events: hospitalisations - 6 months</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.89</p>
|
|
<p>(0.50, 1.60)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events: hospitalisations - time-to-first event (median follow-up 2.1 years)</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2,141</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.01</p>
|
|
<p>(0.94, 1.09)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No meaningful difference</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events: vascular access thrombosis - time-to-first event (median follow-up 2.1 years)</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2,141</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.15</p>
|
|
<p>(0.98, 1.35)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>e</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blood transfusion - time-to-first event (median follow-up 2.1 years)</td><td headers="hd_h_niceng203er11.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2,141</td><td headers="hd_h_niceng203er11.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.84</p>
|
|
<p>(0.71, 1.00)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>e</sup></td><td headers="hd_h_niceng203er11.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng203er11.tab9_1"><p class="no_margin">Serious risk of bias; very serious imprecision</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng203er11.tab9_2"><p class="no_margin">Serious risk of bias; serious imprecision</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng203er11.tab9_3"><p class="no_margin">Serious risk of bias; serious inconsistency; serious imprecision</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng203er11.tab9_4"><p class="no_margin">Serious risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>(e)</dt><dd><div id="niceng203er11.tab9_5"><p class="no_margin">Serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab10"><div id="niceng203er11.tab10" class="table"><h3><span class="label">Table 10</span><span class="title">IV iron dextran MW 267,000 vs IV iron dextran MW 96,000, adults</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng203er11.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcome</th><th id="hd_h_niceng203er11.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng203er11.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng203er11.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng203er11.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - week 1</td><td headers="hd_h_niceng203er11.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng203er11.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.59</p>
|
|
<p>(−0.16, 1.34)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - week 2</td><td headers="hd_h_niceng203er11.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng203er11.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.30</p>
|
|
<p>(−0.49, 1.09)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - week 3</td><td headers="hd_h_niceng203er11.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng203er11.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.77</p>
|
|
<p>(0.08, 1.46)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours MW 267,000. Clinically significant effect higher than the MID (0.42)</td></tr><tr><td headers="hd_h_niceng203er11.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb g/dL - week 4</td><td headers="hd_h_niceng203er11.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng203er11.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 0.77</p>
|
|
<p>(0.06, 1.48)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Favours MW 267,000. Clinically significant effect higher than the MID (0.46)</td></tr><tr><td headers="hd_h_niceng203er11.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serum ferritin μg/L - week 1</td><td headers="hd_h_niceng203er11.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng203er11.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 341.50</p>
|
|
<p>(−386.54, 1069.54)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serum ferritin μg/L - week 2</td><td headers="hd_h_niceng203er11.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng203er11.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 5.20</p>
|
|
<p>(−85.87, 96.27)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serum ferritin μg/L - week 3</td><td headers="hd_h_niceng203er11.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng203er11.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 3.70</p>
|
|
<p>(−84.66, 92.06)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serum ferritin μg/L - week 4</td><td headers="hd_h_niceng203er11.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng203er11.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD −24.10</p>
|
|
<p>(−113.35, 65.15)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng203er11.tab10_1"><p class="no_margin">Very serious risk of bias; serious imprecision</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng203er11.tab10_2"><p class="no_margin">Very serious risk of bias; very serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab11"><div id="niceng203er11.tab11" class="table"><h3><span class="label">Table 11</span><span class="title">IV iron sucrose (500mg) vs IV iron isomaltoside 1000 (500mg), adults, week 6</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab11_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng203er11.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcome</th><th id="hd_h_niceng203er11.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng203er11.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng203er11.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng203er11.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hb >12.5 g/dL</td><td headers="hd_h_niceng203er11.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">341</td><td headers="hd_h_niceng203er11.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.98</p>
|
|
<p>(0.49, 1.96)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality</td><td headers="hd_h_niceng203er11.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">351</td><td headers="hd_h_niceng203er11.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.28</p>
|
|
<p>(0.01, 5.46)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>b</sup></td><td headers="hd_h_niceng203er11.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adverse events</td><td headers="hd_h_niceng203er11.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">346</td><td headers="hd_h_niceng203er11.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.06</p>
|
|
<p>(0.85, 1.33)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE<sup>b</sup></td><td headers="hd_h_niceng203er11.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng203er11.tab11_1"><p class="no_margin">Very serious imprecision</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng203er11.tab11_2"><p class="no_margin">Serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab12"><div id="niceng203er11.tab12" class="table"><h3><span class="label">Table 12</span><span class="title">IV iron sucrose (1000mg) vs IV ferric chloride hexahydrate (1000mg), adults, week 10</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab12_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng203er11.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcome</th><th id="hd_h_niceng203er11.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng203er11.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng203er11.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng203er11.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serum ferritin μg/L</td><td headers="hd_h_niceng203er11.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56</td><td headers="hd_h_niceng203er11.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 129.00</p>
|
|
<p>(−34.41, 292.41)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Haematocrit (%)</td><td headers="hd_h_niceng203er11.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56</td><td headers="hd_h_niceng203er11.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 1.00</p>
|
|
<p>(−0.83, 2.83)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng203er11.tab12_1"><p class="no_margin">Serious risk of bias; serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng203er11tab13"><div id="niceng203er11.tab13" class="table"><h3><span class="label">Table 13</span><span class="title">IV ferric saccharate (100mg/week) vs IV ferric saccharate (2 × 50mg/week), adults, 2 months</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.tab13/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.tab13_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng203er11.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcome</th><th id="hd_h_niceng203er11.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng203er11.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng203er11.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_niceng203er11.tab13_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Interpretation of effect</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serum ferritin μg/L</td><td headers="hd_h_niceng203er11.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td><td headers="hd_h_niceng203er11.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD 9.00</p>
|
|
<p>(−49.90, 67.90)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>a</sup></td><td headers="hd_h_niceng203er11.tab13_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr><tr><td headers="hd_h_niceng203er11.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Haematocrit (%)</td><td headers="hd_h_niceng203er11.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td><td headers="hd_h_niceng203er11.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>MD −2.80</p>
|
|
<p>(−6.20, 0.60)</p>
|
|
</td><td headers="hd_h_niceng203er11.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW<sup>b</sup></td><td headers="hd_h_niceng203er11.tab13_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Could not differentiate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng203er11.tab13_1"><p class="no_margin">Very serious risk of bias; very serious imprecision</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng203er11.tab13_2"><p class="no_margin">Very serious risk of bias; serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng203er11appktab1"><div id="niceng203er11.appk.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.appk.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.appk.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reason for exclusion</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Adhikary, L and Acharya, S (2011) Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy. JNMA; journal of the nepal medical association
|
|
51(183): 133–136 [<a href="https://pubmed.ncbi.nlm.nih.gov/22922860" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22922860</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Not a relevant study design</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Agarwal, Rajiv; Kusek, John W; Pappas, Maria K (2015) A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney international
|
|
88(4): 905–14 [<a href="/pmc/articles/PMC4589436/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4589436</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26083656" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26083656</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Does not contain a population of people on dialysis</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Agarwal, Rajiv, Leehey, David J, Olsen, Scott M
|
|
et al. (2011) Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial. Clinical journal of the American Society of Nephrology : CJASN
|
|
6(1): 114–21 [<a href="/pmc/articles/PMC3022232/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3022232</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20876669" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20876669</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Does not contain a population of people on dialysis</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ahsan, N (2000) Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial. Advances in peritoneal dialysis. Conference on peritoneal dialysis
|
|
16: 80–84 [<a href="https://pubmed.ncbi.nlm.nih.gov/11045266" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11045266</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Albaramki
|
|
Jumana, Hodson
|
|
Elisabeth M, Craig
|
|
Jonathan C, Webster
|
|
Angela C (2012) Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database of Systematic Reviews: Reviews issue1 [<a href="https://pubmed.ncbi.nlm.nih.gov/22258974" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22258974</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Albaramki
|
|
Jumana, Hodson
|
|
Elisabeth M, Craig
|
|
Jonathan C, Webster
|
|
Angela C (2012) Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database of Systematic Reviews: Reviews issue1 [<a href="https://pubmed.ncbi.nlm.nih.gov/22258974" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22258974</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Duplicate reference</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Allegra, V; Mengozzi, G; Vasile, A (1991) Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron
|
|
57(2): 175–182 [<a href="https://pubmed.ncbi.nlm.nih.gov/1902285" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1902285</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Not a relevant study design</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Anirban, Ganguli, Kohli, H S, Jha, Vivekanand
|
|
et al. (2008) The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Renal failure
|
|
30(6): 629–38 [<a href="https://pubmed.ncbi.nlm.nih.gov/18661414" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18661414</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Does not contain a population of people on dialysis</p>
|
|
<p>Mixed conservative management and RRT</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Auerbach, M, Winchester, J, Wahab, A
|
|
et al. (1998) A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation
|
|
31(1): 81–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/9428456" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9428456</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Data not reported in an extractable format</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bregman
|
|
D.B. and Goodnough
|
|
L.T. (2014) Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Therapeutic Advances in Hematology
|
|
5(2): 48–60 [<a href="/pmc/articles/PMC3949301/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3949301</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24688754" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24688754</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Broumand, B, Ghods, A, Taheri, FM
|
|
et al. (1998) Intravenous versus oral iron supplementation in the management of anemia in end stage renal disease. 35th congress. European renal association. European dialysis and transplantation association; 1998 jun 6–9; rimini, italy: 330
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Full text paper not available</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Chertow, Glenn M, Mason, Phillip D, Vaage-Nilsen, Odd
|
|
et al. (2004) On the relative safety of parenteral iron formulations. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
|
|
19(6): 1571–5 [<a href="https://pubmed.ncbi.nlm.nih.gov/15150356" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15150356</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Not a relevant study design</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
DeVita, M V, Frumkin, D, Mittal, S
|
|
et al. (2003) Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clinical nephrology
|
|
60(5): 335–40 [<a href="https://pubmed.ncbi.nlm.nih.gov/14640239" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14640239</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study does not contain a relevant intervention</p>
|
|
<p>RCT using single formulation but with different target levels for Hb</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Dull, R B and Davis, E (2015) Heme iron polypeptide for the management of anaemia of chronic kidney disease. Journal of clinical pharmacy and therapeutics
|
|
40(4): 386–90 [<a href="https://pubmed.ncbi.nlm.nih.gov/25953602" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25953602</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study does not contain a relevant intervention</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Fishbane
|
|
S., Shapiro
|
|
W., Dutka
|
|
P.
|
|
et al. (2001) A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney International
|
|
60(6): 2406–2411 [<a href="https://pubmed.ncbi.nlm.nih.gov/11737617" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11737617</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study does not contain a relevant intervention</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Fishbane, S; Frei, G L; Maesaka, J (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American journal of kidney diseases : the official journal of the National Kidney Foundation
|
|
26(1): 41–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/7611266" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7611266</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Comparator in study does not match that specified in protocol</p>
|
|
<p>iv vs oral</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Fudin, R, Jaichenko, J, Shostak, A
|
|
et al. (1998) Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron
|
|
79(3): 299–305 [<a href="https://pubmed.ncbi.nlm.nih.gov/9678430" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9678430</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Comparator in study does not match that specified in protocol</p>
|
|
<p>no vs iv vs oral</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Fukao, Wataru, Hasuike, Yukiko, Yamakawa, Tomo
|
|
et al. (2018) Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
|
|
28(4): 270–277 [<a href="https://pubmed.ncbi.nlm.nih.gov/29703633" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29703633</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gillespie, Robert S and Wolf, Fredric M (2004) Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatric nephrology (Berlin, Germany)
|
|
19(6): 662–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/15052462" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15052462</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gupta, A, Amin, NB, Besarab, A
|
|
et al. (1999) Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney international
|
|
55(5): 1891–1898 [<a href="https://pubmed.ncbi.nlm.nih.gov/10231452" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10231452</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Not a relevant study design</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hougen
|
|
I., Collister
|
|
D., Bourrier
|
|
M.
|
|
et al. (2018) Safety of intravenous iron in dialysis: A systematic review and meta-analysis. Clinical Journal of the American Society of Nephrology
|
|
13(3): 457–467 [<a href="/pmc/articles/PMC5967668/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5967668</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29463597" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29463597</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Jacobs, Claude; Frei, Dieter; Perkins, Alan C (2005) Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
|
|
20suppl3: iii3–24 [<a href="https://pubmed.ncbi.nlm.nih.gov/15824128" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15824128</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Not a relevant study design</p>
|
|
<p>- Study does not contain a relevant intervention</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Johnson, DW, Herzig, KA, Gissane, R
|
|
et al. (2001) A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients. Nephrology, dialysis, transplantation
|
|
16(9): 1879–1884 [<a href="https://pubmed.ncbi.nlm.nih.gov/11522873" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11522873</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kao, H H, Chen, K S, Tsai, C J
|
|
et al. (2000) Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy. Chang Gung medical journal
|
|
23(10): 608–13 [<a href="https://pubmed.ncbi.nlm.nih.gov/11126152" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11126152</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Full text paper not available</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kato, A, Hamada, M, Suzuki, T
|
|
et al. (2001) Effect of weekly or successive iron supplementation on erythropoietin doses in patients receiving hemodialysis. Nephron
|
|
89(1): 110–112 [<a href="https://pubmed.ncbi.nlm.nih.gov/11528242" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11528242</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kotaki, M, Uday, K, Henriquez, M
|
|
et al. (1997) Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin. Clinical nephrology
|
|
48(1): 63–4 [<a href="https://pubmed.ncbi.nlm.nih.gov/9247787" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9247787</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Letter to editor</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kuji
|
|
T., Toya
|
|
Y., Fujikawa
|
|
T.
|
|
et al. (2015) Acceleration of iron utilization after intravenous iron administration during activated erythropoiesis in hemodialysis patients: A randomized study. Therapeutic Apheresis and Dialysis
|
|
19(2): 131–137 [<a href="https://pubmed.ncbi.nlm.nih.gov/25257861" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25257861</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Aim of study does not match protocol to evaluate the effect of different timings of iron administration during erythropoiesis activated by continuous erythropoietin receptor activator (CERA) on reticulocyte iron uptake</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kuragano, T, Yahiro, M, Kida, A
|
|
et al. (2014) Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis. International journal of artificial organs
|
|
37(12): 865–874 [<a href="https://pubmed.ncbi.nlm.nih.gov/25450320" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25450320</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study does not contain a relevant intervention mixture of oral and sometimes IV iron</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Leehey, David J, Palubiak, David J, Chebrolu, Srivasa
|
|
et al. (2005) Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
|
|
20(1): 135–40 [<a href="https://pubmed.ncbi.nlm.nih.gov/15522899" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15522899</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- NAC was given prior to each iron infusion to prevent oxidative stress</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Li, H and Wang, SX (2009) Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Zhonghua yi xue za zhi
|
|
89(7): 457–462 [<a href="https://pubmed.ncbi.nlm.nih.gov/19567093" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19567093</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study not reported in English</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Li, Han and Wang, Shi-xiang (2008) Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood purification
|
|
26(2): 151–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/18212498" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18212498</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Li, Han and Wang, Shi-Xiang (2008) Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
|
|
28(2): 149–54 [<a href="https://pubmed.ncbi.nlm.nih.gov/18332450" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18332450</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Macdougall
|
|
I.C., Tucker
|
|
B., Thompson
|
|
J.
|
|
et al. (1996) A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney International
|
|
50(5): 1694–1699 [<a href="https://pubmed.ncbi.nlm.nih.gov/8914038" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8914038</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Macdougall, IC, Bock, A, Carrera, F
|
|
et al. (2013) FIND-CKD: a 56-week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron defi ciency. Journal of the american society of nephrology : JASN
|
|
24(abstracts): 3b
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
McMahon, Lawrence P, Kent, Annette B, Kerr, Peter G
|
|
et al. (2010) Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
|
|
25(3): 920–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/19906658" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19906658</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
McMahon, LP, Kent, AB, Roger, SD
|
|
et al. (2007) IV iron sucrose versus oral iron for the anemia of chronic kidney disease (CKD) - a randomized controlled trial. Journal of the american society of nephrology : JASN
|
|
18(abstractsue): 813a
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Michael, Beckie, Coyne, Daniel W, Fishbane, Steven
|
|
et al. (2002) Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney international
|
|
61(5): 1830–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/11967034" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11967034</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Comparator in study does not match that specified in protocol</p>
|
|
<p>historical control vs placebo vs iv</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Michelis
|
|
R.; Sela
|
|
S.; Kristal
|
|
B. (2005) Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels. Nephrology Dialysis Transplantation
|
|
20(9): 1963–1969 [<a href="https://pubmed.ncbi.nlm.nih.gov/15956071" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15956071</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Not a relevant study design</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
O’Lone, Emma L, Hodson, Elisabeth M, Nistor, Ionut
|
|
et al. (2019) Parenteral versus oral iron therapy for adults and children with chronic kidney disease. The Cochrane database of systematic reviews
|
|
2: cd007857 [<a href="/pmc/articles/PMC6384096/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6384096</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30790278" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30790278</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study does not contain a relevant intervention</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Park, Jongha, Chang, Jai Won, Lee, Jong Soo
|
|
et al. (2009) Efficacy of low-dose i.v. iron therapy in haemodialysis patients. Nephrology (Carlton, Vic.)
|
|
14(8): 716–21 [<a href="https://pubmed.ncbi.nlm.nih.gov/20025679" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20025679</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Pollock, R.F. and Muduma, G. (2020) A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. Journal of Medical Economics
|
|
23(7): 751–759 [<a href="https://pubmed.ncbi.nlm.nih.gov/32208038" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32208038</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Does not contain a population of people on dialysis</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ragab
|
|
M.; Mahmoud
|
|
K.; Ragab
|
|
A. (2007) Maintenance intravenous iron sucrose therapy in children under regular hemodialysis. Journal of Medical Sciences
|
|
7(7): 1112–1116
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rath, Thomas, Florschutz, Kai, Kalb, Klaus
|
|
et al. (2010) Low-molecular-weight iron dextran in the management of renal anaemia in patients on haemodialysis--the IDIRA Study. Nephron. Clinical practice
|
|
114(1): c81–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/19887827" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19887827</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Not a relevant study design</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Roger, Simon D, Tio, Martin, Park, Hyeong-Cheon
|
|
et al. (2017) Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. Nephrology (Carlton, Vic.)
|
|
22(12): 969–976 [<a href="/pmc/articles/PMC5725690/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5725690</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27699922" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27699922</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rozen-Zvi, Benaya, Gafter-Gvili, Anat, Paul, Mical
|
|
et al. (2008) Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation
|
|
52(5): 897–906 [<a href="https://pubmed.ncbi.nlm.nih.gov/18845368" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18845368</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Saltissi, D; Sauvage, D; Westhuyzen, J (1998) Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clinical nephrology
|
|
49(1): 45–48 [<a href="https://pubmed.ncbi.nlm.nih.gov/9491286" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9491286</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Data not reported in an extractable format</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sav, Tansu, Tokgoz, Bulent, Sipahioglu, Murat Hayri
|
|
et al. (2007) Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?. Renal failure
|
|
29(4): 423–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/17497463" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17497463</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Does not contain a population of people on dialysis</p>
|
|
<p>Mixed pop with 35% not on dialysis</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Shepshelovich, Daniel, Rozen-Zvi, Benaya, Avni, Tomer
|
|
et al. (2016) Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation
|
|
68(5): 677–690 [<a href="https://pubmed.ncbi.nlm.nih.gov/27321965" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27321965</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sirken, G; Raja, R; Rizkala, A R (2006) Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clinical nephrology
|
|
66(5): 348–56 [<a href="https://pubmed.ncbi.nlm.nih.gov/17140164" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17140164</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Not a relevant study design</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
St.
|
|
Peter
|
|
W.L.; Lambrecht
|
|
L.J.; Macres
|
|
M. (1996) Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. American Journal of Kidney Diseases
|
|
28(4): 523–528 [<a href="https://pubmed.ncbi.nlm.nih.gov/8840941" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8840941</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Data not reported in an extractable format</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sunder-Plassmann, G and Horl, W H (1995) Importance of iron supply for erythropoietin therapy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
|
|
10(11): 2070–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/8643170" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8643170</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Not a relevant study design</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Susantitaphong, P., Siribumrungwong, M., Takkavatakarn, K.
|
|
et al. (2020) Effect of Maintenance Intravenous Iron Treatment on Erythropoietin Dose in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial. Canadian Journal of Kidney Health and Disease
|
|
7 [<a href="/pmc/articles/PMC7307402/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7307402</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32612843" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32612843</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Study does not contain a relevant intervention</p>
|
|
<p>Unclear what iron supplement was used</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Svára, F, Sulková, S, Kvasnićka, J
|
|
et al. (1996) Iron supplementation during erythropoietin therapy in patients on hemodialysis. Vnitrni lekarstvi
|
|
42(12): 849–852 [<a href="https://pubmed.ncbi.nlm.nih.gov/9072885" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9072885</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Full text paper not available</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Tsuchida
|
|
A., Paudyal
|
|
B., Paudyal
|
|
P.
|
|
et al. (2010) Effectiveness of oral iron to manage anemia in long-term hemodialysis patients with the use of ultrapure dialysate. Experimental and Therapeutic Medicine
|
|
1(5): 777–781 [<a href="/pmc/articles/PMC3445869/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3445869</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22993601" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22993601</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study does not contain a relevant intervention</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Visciano, B, Nazzaro, P, Tarantino, G
|
|
et al. (2013) Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease. Giornale italiano di nefrologia
|
|
30(5) [<a href="https://pubmed.ncbi.nlm.nih.gov/24402627" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24402627</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study not reported in English</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Warady
|
|
B.A., Kausz
|
|
A., Lerner
|
|
G.
|
|
et al. (2004) Iron therapy in the pediatric hemodialysis population. Pediatric Nephrology
|
|
19(6): 655–661 [<a href="https://pubmed.ncbi.nlm.nih.gov/15064942" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15064942</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in protocol</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Weiss, Gunter and Kronenberg, Florian (2015) Intravenous iron administration: new observations and time for the next steps. Kidney international
|
|
87(1): 10–2 [<a href="https://pubmed.ncbi.nlm.nih.gov/25549119" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25549119</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Not a relevant study design</p>
|
|
<p>Commentary</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wingard, R L, Parker, R A, Ismail, N
|
|
et al. (1995) Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. American journal of kidney diseases : the official journal of the National Kidney Foundation
|
|
25(3): 433–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/7872321" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7872321</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study does not contain a relevant intervention</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wu, Chih-Jen, Lin, Hsin-Chang, Lee, Kun-Feng
|
|
et al. (2010) Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients. Nephrology (Carlton, Vic.)
|
|
15(1): 42–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/20377770" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20377770</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Data not reported in an extractable format</p>
|
|
<p>Reported as medians</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Yin, L, Chen, X, Chen, J
|
|
et al. (2012) Multi-frequency low-dose intravenous iron on oxidative stress in maintenance hemodialysis patients. Zhong nan da xue xue bao. Yi xue ban [Journal of Central South University. Medical sciences] 37(8): 844–848 [<a href="https://pubmed.ncbi.nlm.nih.gov/22954919" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22954919</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study not reported in English</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ziedan
|
|
A. and Bhandari
|
|
S. (2019) Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD). Trials
|
|
20(1): 194 [<a href="/pmc/articles/PMC6449958/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6449958</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30947751" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30947751</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Not a relevant study design</p>
|
|
<p>Protocol</p>
|
|
</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Zitt
|
|
E., Sturm
|
|
G., Kronenberg
|
|
F.
|
|
et al. (2014) Iron supplementation and mortality in incident dialysis patients: An observational study. PLoS ONE
|
|
9(12): e114144 [<a href="/pmc/articles/PMC4252084/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4252084</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25462819" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25462819</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Not a relevant study design</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng203er11appktab2"><div id="niceng203er11.appk.tab2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK574724/table/niceng203er11.appk.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng203er11.appk.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reason</th></tr></thead><tbody><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Aiello, Andrea, Berto, Patrizia, Conti, Paolo
|
|
et al. (2020) Economic impact of ferric carboxymaltose in haemodialysis patients. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
|
|
37(suppl75) [<a href="https://pubmed.ncbi.nlm.nih.gov/32749086" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32749086</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study not reported in English</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Besarab, A, Amin, N, Ahsan, M
|
|
et al. (2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. Journal of the American Society of Nephrology: JASN
|
|
11(3): 530–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/10703677" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10703677</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not include quality of life data.</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Bhandari, Sunil (2011) A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Therapeutics and clinical risk management
|
|
7: 103–13 [<a href="/pmc/articles/PMC3071347/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3071347</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21479141" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21479141</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not include quality of life data.</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Dahl
|
|
N.V., Kaper
|
|
R.F., Strauss
|
|
W.E.
|
|
et al. (2017) Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA. ClinicoEconomics and Outcomes Research
|
|
9: 557–567 [<a href="/pmc/articles/PMC5614742/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5614742</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29033594" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29033594</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not include quality of life data.</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Darba, Josep and Ascanio, Meritxell (2018) Budget Impact Analysis of Oral Fisiogen Ferro Forte versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain. Clinical drug investigation
|
|
38(9): 801–811 [<a href="https://pubmed.ncbi.nlm.nih.gov/29934762" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29934762</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not include quality of life data.</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Fragoulakis
|
|
V., Kourlaba
|
|
G., Goumenos
|
|
D.
|
|
et al. (2012) Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece. ClinicoEconomics and Outcomes Research
|
|
4(1): 127–134 [<a href="/pmc/articles/PMC3358814/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3358814</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22629113" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22629113</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not include quality of life data.</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Pollock, R.F. and Muduma, G. (2020) A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. Journal of Medical Economics
|
|
23(7): 751–759 [<a href="https://pubmed.ncbi.nlm.nih.gov/32208038" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32208038</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not contain a population of people with CKD</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Rognoni, Carla, Ortalda, Vittorio, Biasi, Caterina
|
|
et al. (2019) Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy. Advances in therapy
|
|
36(11): 3253–3264 [<a href="/pmc/articles/PMC6822962/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6822962</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31489572" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31489572</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not include quality of life data</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Sepandj, F, Jindal, K, West, M
|
|
et al. (1996) Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association
|
|
11(2): 319–22 [<a href="https://pubmed.ncbi.nlm.nih.gov/8671786" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8671786</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not include quality of life data.</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Wilson, Paul D, Hutchings, Adam, Jeans, Aruna
|
|
et al. (2013) An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. Journal of medical economics
|
|
16(1): 108–14 [<a href="https://pubmed.ncbi.nlm.nih.gov/22989163" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22989163</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not include quality of life data.</td></tr><tr><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
Wong, Germaine, Howard, Kirsten, Hodson, Elisabeth
|
|
et al. (2013) An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association
|
|
28(2): 413–20 [<a href="https://pubmed.ncbi.nlm.nih.gov/23182811" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23182811</span></a>]
|
|
</td><td headers="hd_h_niceng203er11.appk.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Compares oral versus IV rather than IV versus IV iron.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|